First in human safety study of FX-322 in adults undergoing cochlear implantation.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs FX 322 (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Frequency Therapeutics
- 21 Jul 2017 Planned number of patients changed from 12 to 13.
- 21 Jul 2017 Planned End Date changed from 18 Sep 2017 to 18 Nov 2017.
- 21 Jul 2017 Status changed from not yet recruiting to recruiting.